| Year |
Citation |
Score |
| 2022 |
Karthic A, Roy A, Lakkakula J, Alghamdi S, Shakoori A, Babalghith AO, Emran TB, Sharma R, Lima CMG, Kim B, Park MN, Safi SZ, de Almeida RS, Coutinho HDM. Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review. Frontiers in Cell and Developmental Biology. 10: 984311. PMID 36158215 DOI: 10.3389/fcell.2022.984311 |
0.313 |
|
| 2022 |
Velhal K, Barage S, Roy A, Lakkakula J, Yamgar R, Alqahtani MS, Yadav KK, Ahn Y, Jeon BH. A Promising Review on Cyclodextrin Conjugated Paclitaxel Nanoparticles for Cancer Treatment. Polymers. 14. PMID 35956677 DOI: 10.3390/polym14153162 |
0.307 |
|
| 2021 |
Lee YH, Lee MM, De Silva DM, Roy A, Wright CE, Wong TK, Costello R, Olaku O, Grubb RL, Agarwal PK, Apolo AB, Bottaro DP. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. Plos One. 16: e0241766. PMID 34292953 DOI: 10.1371/journal.pone.0241766 |
0.585 |
|
| 2020 |
Roy A. Plumbagin: A potential anti-cancer compound. Mini Reviews in Medicinal Chemistry. PMID 33200707 DOI: 10.2174/1389557520666201116144421 |
0.323 |
|
| 2020 |
Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, ... ... Roy A, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. The Lancet. Oncology. PMID 32645282 DOI: 10.1016/S1470-2045(20)30202-3 |
0.677 |
|
| 2019 |
Maimouni S, Lee MH, Sung YM, Hall M, Roy A, Ouaari C, Hwang YS, Spivak J, Glasgow E, Swift M, Patel J, Cheema A, Kumar D, Byers S. Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival. Oncotarget. 10: 1606-1624. PMID 30899431 DOI: 10.18632/Oncotarget.26600 |
0.409 |
|
| 2017 |
Roy A, Ramalinga M, Kim OJ, Chijioke J, Lynch S, Byers S, Kumar D. Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition. Plos One. 12: e0180344. PMID 28678839 DOI: 10.1371/Journal.Pone.0180344 |
0.39 |
|
| 2017 |
De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP. Targeting the hepatocyte growth factor/Met pathway in cancer. Biochemical Society Transactions. PMID 28673936 DOI: 10.1042/Bst20160132 |
0.699 |
|
| 2017 |
Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. HGF-MET in cancer progression and biomarker discovery. Cancer Science. PMID 28064454 DOI: 10.1111/Cas.13156 |
0.756 |
|
| 2017 |
Roy A, DeSilva DM, Bottaro DP. Abstract 5530: Evidence linking aquaporin-3 loss to increased invasiveness in bladder cancer Cancer Research. 77: 5530-5530. DOI: 10.1158/1538-7445.Am2017-5530 |
0.593 |
|
| 2016 |
Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, Verma M, Kumar D. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Medicine. PMID 27282910 DOI: 10.1002/Cam4.775 |
0.34 |
|
| 2016 |
Silva DD, Lee Y, Roy A, Bottaro DP. Abstract 4575: Altered catalytic properties of a subset of Met cytoplasmic domain variants occurring in renal cell carcinoma Cancer Research. 76: 4575-4575. DOI: 10.1158/1538-7445.Am2016-4575 |
0.697 |
|
| 2015 |
Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, Collins S, Kumar D. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget. PMID 26439987 DOI: 10.18632/Oncotarget.5920 |
0.32 |
|
| 2014 |
Roy A, Kim OJ, Ramalinga M, Lynch S, Byers S, Kumar D. Abstract 590: RARRES1 is a modulator of angiogenesis and autophagy Cancer Research. 74: 590-590. DOI: 10.1158/1538-7445.Am2014-590 |
0.487 |
|
| Show low-probability matches. |